ASH 2019 | Real world experience of tisagenlecleucel for R/R ALL in the US
Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the study of tisagenlecleucel CAR T-cell therapy for relapsed/refractory children and young adults with acute lymphoblastic leukemia (ALL) in the real-world setting. Clinical data from the Center for International Blood and Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry were analyzed and utilized for the study. Dr Grupp highlights that the toxicity levels in the real world setting were considerably lower than in the registration trial. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up